# Clinical Study on the Efficacy and Safety of Hetropapa Ethanolamine Tablets in the Treatment of Thrombocytopenia Caused by Concurrent Radiotherapy and Chemotherapy in Cervical Cancer

> **NCT05160857** · NA · UNKNOWN · sponsor: **Second Hospital of Shanxi Medical University** · enrollment: 30 (estimated)

## Conditions studied

- Tumor Chemotherapy-related Thrombocytopenia

## Interventions

- **DRUG:** Herombopag Olamine

## Key facts

- **NCT ID:** NCT05160857
- **Lead sponsor:** Second Hospital of Shanxi Medical University
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2021-12-31
- **Primary completion:** 2022-12-31
- **Final completion:** 2023-12-31
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2021-12-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05160857

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05160857, "Clinical Study on the Efficacy and Safety of Hetropapa Ethanolamine Tablets in the Treatment of Thrombocytopenia Caused by Concurrent Radiotherapy and Chemotherapy in Cervical Cancer". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT05160857. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*